Skip to main content
AMCP 2025 Main banner
Back

Drugs, Diseases, and the Managed Care Impact

(D1) Charting a Better Path in Managing Multiple Myeloma: Overcoming Challenges and Driving Solutions

Tuesday, April 1, 2025
10:30 AM – 11:45 AM CST
Location: 310
CPE
ACPE UAN:0233-0000-25-003-L01-P | Contact Hours: 1.25 | Activity Type: Knowledge-based
This educational activity is supported by an independent medical education grant from GSK.

Multiple myeloma, a cancer of the plasma cells, presents unique challenges within the managed care pharmacy framework. Over the past 25 years, the 5-year survival rate of patients with multiple myeloma has more than doubled due in part to recent scientific advances, including triplet/quadruplet regimens, bispecific antibodies, and chimeric antigen receptor (CAR) T-cell products. However, such novel therapies pose high healthcare costs, highlighting the need for more effective management and treatments that can mitigate the economic burden of multiple myeloma.

Attendees will gain insights into various real-world, effective strategies for optimizing care delivery and navigating the managed care landscape of multiple myeloma. This session aims to bridge the gap between recent drug advances in the treatment of multiple myeloma and their associated managed care impact to ensure multiple myeloma patients receive the optimal care they deserve.

Learning Objectives:

At the completion of this activity, participants should be able to:
  1. Discuss key drivers increasing the economic burden of multiple myeloma and explore best practices to optimize healthcare resource utilization.
  2. Recognize the clinical landscape of multiple myeloma, including recent advancements in treatment options, clinical guidelines, and future therapies in the pipeline.
  3. Identify common barriers faced by multiple myeloma patients in accessing care and strategies to overcome them
  4. Describe real-world examples of managed care strategies that successfully improve patient management and cost-effectiveness.